Loading stock…

Cellebrite DI Ltd. (CLBT) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

CLBTCellebrite DI

Revenue FY25$476M

GROWTH RATING↗

VERY STRONG87 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+21%9

Revenue, next 1Y+17%8

Revenue, next 3Y, CAGR+16%8

Revenue, next 5Y, CAGR+15%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+81%10

EPS growth, FY27E+20%8

EPS growth, FY28E+20%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 87% of companies worldwide.

Revenue grew 21%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 16%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 15%/yr over five years.9/10

Earnings are set to grow in step with sales (EPS about 20%/yr vs revenue 16%/yr).

WATCH

Revenue grew 21%/yr over the last 3 years; forecasts see it cooling to 16%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

CLBTCellebrite DI

Total return Current8.0%

Price return Current8.0%

MOMENTUM RATING↗

VERY WEAK14 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-1%7

3-month return-31%1

YTD return-37%1

MID & LONG-TERM▾SCORE

% of 52-week high57%2

1-year return-39%1

3-year return+50%5

5-year return+14%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-1%).

WATCH

Average long-term results. Multi-year returns are middling (+50% over three years and +14% over five), roughly average for the market.

WEAKNESSES

It's down 39% over the past year, now 43% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-31%) and so far this year (-37%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Cellebrite DI Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

CLBTCellebrite DI

Revenue FY25$476M

GROWTH RATING↗

VERY STRONG87 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+21%9

Revenue, next 1Y+17%8

Revenue, next 3Y, CAGR+16%8

Revenue, next 5Y, CAGR+15%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+81%10

EPS growth, FY27E+20%8

EPS growth, FY28E+20%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 87% of companies worldwide.

Revenue grew 21%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 16%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 15%/yr over five years.9/10

Earnings are set to grow in step with sales (EPS about 20%/yr vs revenue 16%/yr).

WATCH

Revenue grew 21%/yr over the last 3 years; forecasts see it cooling to 16%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

CLBTCellebrite DI

Total return Current8.0%

Price return Current8.0%

MOMENTUM RATING↗

VERY WEAK14 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-1%7

3-month return-31%1

YTD return-37%1

MID & LONG-TERM▾SCORE

% of 52-week high57%2

1-year return-39%1

3-year return+50%5

5-year return+14%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-1%).

WATCH

Average long-term results. Multi-year returns are middling (+50% over three years and +14% over five), roughly average for the market.

WEAKNESSES

It's down 39% over the past year, now 43% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-31%) and so far this year (-37%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Cellebrite DI Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Cellebrite DI Ltd.

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Cellebrite DI Ltd.. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Cellebrite DI Ltd.. Get the full investment case.

Premium